Insulin degludec/Liraglutide(Huisheng Biopharmaceutical)

德谷胰岛素利拉鲁肽（惠升生物）

Report date: 2023/10/23 16:34:37

Base Information

Drug NameInsulin degludec/Liraglutide(Huisheng Biopharmaceutical)

Drug Alias Nameinsulinum degludecum/liraglutidum地谷胰岛素/利拉鲁肽GLP-1 and basal insulin combination地谷胰岛素/利拉糖肽insulina degludec/liraglutida +[9]

ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Protein drugs > Recombinant polypeptideBiologics > Biosimilar

Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsInsulin receptor agonists

TargetsGlucagon-like peptide 1 receptorInsulin receptor

Therapy Area/IndicationsDiabetes Mellitus, Type 2

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsYes

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesJilin Huisheng Biopharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesJilin Huisheng Biopharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsDiabetes Mellitus, Type 2

Inactive IndicationsN/A

Other Information

ATC CodeN/A